| Literature DB >> 33980150 |
Jochem C G Scheijmans1, Alexander B J Borgstein2, Jan M Prins3, Hester A Gietema4, Jaap Stoker5, Suzanne S Gisbertz2, Marc G H Besselink2, Marja A Boermeester6, Carl A J Puylaert5, Wouter J Bom1, Said Bachiri7, Eduard A van Bodegraven8, Amarins T A Brandsma9, Floor M Ter Brugge10, Steve M M de Castro11, Roy Couvreur12, Lotte C Franken13, Marcia P Gaspersz14, Michelle R de Graaff15, Hannah Groenen16, Suzanne C Kleipool11, Toon J L Kuypers17, Milou H Martens18, David M Mens19, Ricardo G Orsini20, Nando J M M Reneerkens21, Thomas Schok22, Wouter J A Sedee23, Shahzad Tavakoli Rad24, José H Volders25, Pepijn D Weeder26.
Abstract
BACKGROUND: During the COVID-19 pandemic, a decrease in the number of patients presenting with acute appendicitis was observed. It is unclear whether this caused a shift towards more complicated cases of acute appendicitis. We compared a cohort of patients diagnosed with acute appendicitis during the 2020 COVID-19 pandemic with a 2019 control cohort.Entities:
Keywords: Acute appendicitis; COVID-19 pandemic; Complicated appendicitis
Year: 2021 PMID: 33980150 PMCID: PMC8114672 DOI: 10.1186/s12873-021-00454-y
Source DB: PubMed Journal: BMC Emerg Med ISSN: 1471-227X
Fig. 1Flowchart: inclusions SCOUT-4 study cohort versus 2020
Fig. 2Daily presentations of patients with acute appendicitis
Baseline: clinical characteristics of all patients, 2019 pre-COVID cohort compared to 2020 COVID cohort
| Characteristic | 2019 control cohort ( | 2020 COVID-19 cohort | |
|---|---|---|---|
| Age, median (IQR), years | 40 (28–57) | 42 (29–58) | 0.183 |
| Female sex, no./total no. (%) | 322/642 (50.2) | 318/607 (52.4) | 0.430 |
| ASA > 1, no./total no. (%) | 263/595 (44.2) | 254/524 (48.5) | 0.153 |
| COPD, no./total no. (%) | 13/630 (2.1) | 11/599 (1.8) | 0.774 |
| Diabetes Mellitus, no./total no. (%) | 24/631 (3.8) | 34/596 (5.7) | 0.117 |
| Heart failure, no./total no. (%) | 11/631 (1.7) | 11/597 (1.8) | 0.896 |
| Coronary artery disease, no./total no. (%) | 17/631 (2.7) | 28/598 (4.7) | 0.064 |
| Active smoker, no./total no. (%) | 61/293 (20.8) | 63/275 (22.9) | 0.547 |
| Duration of symptoms > 24 h, no./total no. (%) | 358/637 (56.2) | 371/601 (61.1) | |
| Severity of appendicitis, no./total no. (%) | |||
| Uncomplicated | 391/642 (60.9) | 321/607 (52.9) | |
| Gangrenous | 45/642 (7.0) | 50/607 (8.2) | |
| Perforation | 157/642 (24.5) | 179/607 (29.5) | |
| Infiltrate/Abscess | 43/642 (6.7) | 54/607 (8.9) | |
| Normal (sana) | 6/642 (0.9) | 3/607 (0.5) | |
| Conservative treatment, no./total no. (%) | 41/642 (6.4) | 63/607 (10.4) | |
| Complication within 30 days, no./total no. (%) | 72/642 (11.5) | 76/607 (12.5) | 0.475 |
Abbreviations: ASA American Society of Anesthesiologists, COPD Chronic Obstructive Pulmonary Disease, IQR interquartile range
Fig. 3Total number of patients, stratified by type of acute appendicitis: 2019 control cohort vs. 2020 COVID cohort
Comparison of patients with complicated appendicitis for 2019 pre-COVID cohort vs. 2020 COVID cohort
| Characteristic | 2019 control cohort ( | 2020 COVID-19 cohort ( | |
|---|---|---|---|
| Age, median (IQR), years | 49 (33–65) | 50 (32–64) | 0.946 |
| ASA > 1, no./total no. (%) | 126/225 (56.0) | 131/239 (54.8) | 0.797 |
| Duration of symptoms > 24 h, no./total no. (%) | 164/241 (68.0) | 214/281 (76.2) | |
| Types of complicated appendicitis, no./total no. (%) | |||
| Gangrenous | 45/245 (18.4) | 50/283 (17.7) | 0.835 |
| Perforation | 157/245 (64.1) | 179/283 (63.3) | 0.843 |
| Abscess or infiltrate | 43/245 (17.6) | 54/283 (19.1) | 0.651 |
| Conservative treatment, no./total no. (%) | 31/245 (12.7) | 41/283 (14.5) | 0.540 |
| In-hospital delay in operated patients, median (IQR), hours | 7.8 (5.0–13.3) | 6.7 (4.6–12.1) | 0.152 |
| Postoperative complicationa, no./total no. (%) | 40/214 (18.7) | 45/242 (18.6) | 0.979 |
| Severe postoperative complicationa b, no./total no. (%) | 11/245 (5.1) | 13/281 (5.4) | 0.904 |
Abbreviations: ASA American Society of Anesthesiologists, IQR interquartile range
aPatients for whom surgery was the initial treatment
bSevere complications are defined as Clavien-Dindo IIIa or higher
Characteristics and outcomes of patients with appendicitis, stratified for duration of symptoms, ≤24 h vs. > 24 h, in 2019 pre-COVID cohort and 2020 COVID cohort
| Characteristic | 2019 control cohort ( | 2020 COVID-19 cohort ( | ||||
|---|---|---|---|---|---|---|
| ≤ 24 h ( | > 24 h ( | ≤ 24 h ( | > 24 h ( | |||
| Age, median (IQR), years | 40 (28–55) | 41 (27–58) | 0.707 | 37 (28–52) | 45 (31–60) | |
| Age ≥ 60 years, no./total no. (%) | 54/279 (19.4) | 82/358 (22.9) | 0.278 | 37/230 (16.1) | 96/371 (25.9) | |
| Female sex, no./total no. (%) | 151/279 (54.1) | 169/358 (47.2) | 0.083 | 124/230 (53.9) | 189/371 (50.9) | 0.479 |
| ASA > 1, no./total no. (%) | 115/263 (43.7) | 145/327 (44.3) | 0.881 | 106/211 (50.2) | 145/309 (46.9) | 0.458 |
| Comorbidity, no./total no. (%) | 22/273 (8.1) | 24/348 (6.9) | 0.583 | 20/223 (9.0) | 44/363 (12.1) | 0.235 |
| Severity of appendicitis, no./total no. (%) | ||||||
| Uncomplicated | 201/279 (72.0) | 189/358 (52.8) | 163/230 (70.9) | 154/371 (41.5) | ||
| Gangrenous | 26/279 (9.3) | 19/358 (5.3) | 17/230 (7.4) | 32/371 (8.6) | ||
| Perforation | 44/279 (15.8) | 109/358 (30.4) | 41/230 (17.8) | 137/371 (36.9) | ||
| Infiltration/abscess | 7/279 (2.5) | 36/358 (10.1) | 9/230 (3.9) | 45/371 (12.1) | ||
| Normal (sana) | 1/279 (0.4) | 5/358 (1.4) | 0/230 (0) | 3/371 (0.8) | ||
| Conservative treatment, no./total no. (%) | 8/279 (2.9) | 33/358 (9.2) | 5/230 (2.2) | 57/371 (15.4) | ||
| In-hospital delay in operated patients, median (IQR), hours | 7.6 (5.0–14.7) | 7.0 (4.8–11.8) | 0.076 | 7.2 (4.4–13.2) | 6.2 (4.3–10.0) | 0.057 |
| Complication within 30 days, no./total no. (%) | 28/279 (10.0) | 42/358 (11.7) | 0.292 | 16/230 (7.0) | 60/371 (16.2) | |
| Postoperative complicationc, no./total no. (%) | 26/271 (9.6) | 41/325 (12.6) | 0.245 | 15/225 (6.7) | 48/313 (15.3) | |
| Severe postoperative complicationc d, no./total no. (%) | 4/271 (1.5) | 10/325 (3.1) | 0.279a | 5/225 (2.2) | 15/313 (4.8) | 0.165a |
Abbreviations: ASA American Society of Anesthesiologists, IQR interquartile range
aFischer exact test was performed
bIn 2019 5 patients and in 2020 6 patients missed data about the duration of symptoms
cPatients for whom surgery was the initial treatment
dSevere complications are defined as Clavien-Dindo IIIa or higher